Last reviewed · How we verify
influenza vaccine（BK01 adjuvnat）
influenza vaccine（BK01 adjuvnat） is a Biologic drug developed by Changchun BCHT Biotechnology Co.. It is currently in Phase 1 development.
At a glance
| Generic name | influenza vaccine（BK01 adjuvnat） |
|---|---|
| Sponsor | Changchun BCHT Biotechnology Co. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- influenza vaccine（BK01 adjuvnat） CI brief — competitive landscape report
- influenza vaccine（BK01 adjuvnat） updates RSS · CI watch RSS
- Changchun BCHT Biotechnology Co. portfolio CI
Frequently asked questions about influenza vaccine（BK01 adjuvnat）
What is influenza vaccine（BK01 adjuvnat）?
influenza vaccine（BK01 adjuvnat） is a Biologic drug developed by Changchun BCHT Biotechnology Co..
Who makes influenza vaccine（BK01 adjuvnat）?
influenza vaccine（BK01 adjuvnat） is developed by Changchun BCHT Biotechnology Co. (see full Changchun BCHT Biotechnology Co. pipeline at /company/changchun-bcht-biotechnology-co).
What development phase is influenza vaccine（BK01 adjuvnat） in?
influenza vaccine（BK01 adjuvnat） is in Phase 1.